New data on the pharmacokinetics of adriamycin and its major metabolite, adriamycinol. 1991

F Leca, and D Marchiset-Leca, and A Noble, and M Antonetti
Laboratoire de Pharmacocinétique, C.H.D. Castelluccio, Ajaccio, France.

Twenty-two days after administration by intravenous bolus, of 50 mg of adriamycin to several patients we found concentrations of adriamycin and adriamycinol of the order of 100 pcg/ml. In theory, however, with a terminal half-life of 30 h, the plasma levels of adriamycin and adriamycinol should be close to 0.1 pcg/ml. Further pharmacokinetic investigation was therefore necessary. We have retained for this study nine male patients, aged between 53 and 69 years who received 25 to 50 mg of adriamycin by slow intravenous injection. The HPLC method permitted the detection of 50 pcg/ml of adriamycin and adriamycinol, with the possibility of monitoring their elimination during 120 h (and in one case during 160 h). The terminal half-lives of elimination estimated in 8 patients were respectively 110 +/- 52 h for adriamycin and 92 h 50 min +/- 43 h for adriamycinol. Surface ratios under adriamycinol curves against calculated adriamycin was 1.10 +/- 0.26. Plasma levels found during the To in certain patients correspond to the end of the drug elimination of the previous treatment. It is difficult with a half-life to 110 h to predict the effects of residual concentrations of adriamycin and adriamycinol.

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D002851 Chromatography, High Pressure Liquid Liquid chromatographic techniques which feature high inlet pressures, high sensitivity, and high speed. Chromatography, High Performance Liquid,Chromatography, High Speed Liquid,Chromatography, Liquid, High Pressure,HPLC,High Performance Liquid Chromatography,High-Performance Liquid Chromatography,UPLC,Ultra Performance Liquid Chromatography,Chromatography, High-Performance Liquid,High-Performance Liquid Chromatographies,Liquid Chromatography, High-Performance
D004317 Doxorubicin Antineoplastic antibiotic obtained from Streptomyces peucetius. It is a hydroxy derivative of DAUNORUBICIN. Adriamycin,Adriablastin,Adriablastine,Adriblastin,Adriblastina,Adriblastine,Adrimedac,DOXO-cell,Doxolem,Doxorubicin Hexal,Doxorubicin Hydrochloride,Doxorubicin NC,Doxorubicina Ferrer Farm,Doxorubicina Funk,Doxorubicina Tedec,Doxorubicine Baxter,Doxotec,Farmiblastina,Myocet,Onkodox,Ribodoxo,Rubex,Urokit Doxo-cell,DOXO cell,Hydrochloride, Doxorubicin,Urokit Doxo cell
D006207 Half-Life The time it takes for a substance (drug, radioactive nuclide, or other) to lose half of its pharmacologic, physiologic, or radiologic activity. Halflife,Half Life,Half-Lifes,Halflifes
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly

Related Publications

F Leca, and D Marchiset-Leca, and A Noble, and M Antonetti
January 1987, Journal of cancer research and clinical oncology,
F Leca, and D Marchiset-Leca, and A Noble, and M Antonetti
June 1997, Research communications in molecular pathology and pharmacology,
F Leca, and D Marchiset-Leca, and A Noble, and M Antonetti
January 1983, Cancer chemotherapy and pharmacology,
F Leca, and D Marchiset-Leca, and A Noble, and M Antonetti
February 2000, Talanta,
F Leca, and D Marchiset-Leca, and A Noble, and M Antonetti
November 1985, Xenobiotica; the fate of foreign compounds in biological systems,
F Leca, and D Marchiset-Leca, and A Noble, and M Antonetti
January 1982, Journal of chromatography,
F Leca, and D Marchiset-Leca, and A Noble, and M Antonetti
January 2008, Cardiovascular therapeutics,
F Leca, and D Marchiset-Leca, and A Noble, and M Antonetti
September 2008, Archives of pharmacal research,
Copied contents to your clipboard!